nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR1D—autistic disorder	0.501	0.627	CbGaD
Dihydroergotamine—HTR1B—autistic disorder	0.297	0.372	CbGaD
Dihydroergotamine—HTR1B—telencephalic ventricle—autistic disorder	0.00591	0.0888	CbGeAlD
Dihydroergotamine—HTR1D—telencephalic ventricle—autistic disorder	0.00573	0.086	CbGeAlD
Dihydroergotamine—HTR1A—telencephalic ventricle—autistic disorder	0.00477	0.0716	CbGeAlD
Dihydroergotamine—HTR6—forebrain—autistic disorder	0.00256	0.0385	CbGeAlD
Dihydroergotamine—HTR6—telencephalon—autistic disorder	0.00236	0.0354	CbGeAlD
Dihydroergotamine—HTR1A—hindbrain—autistic disorder	0.00225	0.0338	CbGeAlD
Dihydroergotamine—HTR1B—brainstem—autistic disorder	0.0016	0.024	CbGeAlD
Dihydroergotamine—HTR1D—brainstem—autistic disorder	0.00155	0.0233	CbGeAlD
Dihydroergotamine—Ergoloid mesylate—DRD1—autistic disorder	0.00155	0.231	CrCbGaD
Dihydroergotamine—HTR1B—forebrain—autistic disorder	0.00154	0.0232	CbGeAlD
Dihydroergotamine—HTR1D—eye—autistic disorder	0.00151	0.0226	CbGeAlD
Dihydroergotamine—HTR1D—forebrain—autistic disorder	0.0015	0.0224	CbGeAlD
Dihydroergotamine—HTR6—head—autistic disorder	0.00147	0.022	CbGeAlD
Dihydroergotamine—HTR1B—telencephalon—autistic disorder	0.00142	0.0213	CbGeAlD
Dihydroergotamine—HTR6—nervous system—autistic disorder	0.00139	0.0209	CbGeAlD
Dihydroergotamine—HTR2B—forebrain—autistic disorder	0.00139	0.0209	CbGeAlD
Dihydroergotamine—HTR1D—telencephalon—autistic disorder	0.00137	0.0206	CbGeAlD
Dihydroergotamine—HTR6—central nervous system—autistic disorder	0.00134	0.0201	CbGeAlD
Dihydroergotamine—HTR1A—brainstem—autistic disorder	0.00129	0.0194	CbGeAlD
Dihydroergotamine—HTR2B—telencephalon—autistic disorder	0.00128	0.0192	CbGeAlD
Dihydroergotamine—HTR1A—forebrain—autistic disorder	0.00125	0.0187	CbGeAlD
Dihydroergotamine—HTR1A—telencephalon—autistic disorder	0.00115	0.0172	CbGeAlD
Dihydroergotamine—Ergotamine—HTR1D—autistic disorder	0.00107	0.159	CrCbGaD
Dihydroergotamine—HTR6—brain—autistic disorder	0.00106	0.016	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR1D—autistic disorder	0.00103	0.154	CrCbGaD
Dihydroergotamine—HTR2B—digestive system—autistic disorder	0.000976	0.0147	CbGeAlD
Dihydroergotamine—HTR1B—head—autistic disorder	0.000884	0.0133	CbGeAlD
Dihydroergotamine—ADRA2A—forebrain—autistic disorder	0.000873	0.0131	CbGeAlD
Dihydroergotamine—HTR1D—head—autistic disorder	0.000856	0.0129	CbGeAlD
Dihydroergotamine—HTR1B—nervous system—autistic disorder	0.000838	0.0126	CbGeAlD
Dihydroergotamine—HTR1D—nervous system—autistic disorder	0.000812	0.0122	CbGeAlD
Dihydroergotamine—HTR1B—central nervous system—autistic disorder	0.000807	0.0121	CbGeAlD
Dihydroergotamine—ADRA2A—telencephalon—autistic disorder	0.000803	0.0121	CbGeAlD
Dihydroergotamine—HTR2B—head—autistic disorder	0.000796	0.012	CbGeAlD
Dihydroergotamine—HTR1D—central nervous system—autistic disorder	0.000781	0.0117	CbGeAlD
Dihydroergotamine—HTR2B—nervous system—autistic disorder	0.000755	0.0113	CbGeAlD
Dihydroergotamine—HTR2B—central nervous system—autistic disorder	0.000727	0.0109	CbGeAlD
Dihydroergotamine—HTR1A—head—autistic disorder	0.000714	0.0107	CbGeAlD
Dihydroergotamine—HTR1A—nervous system—autistic disorder	0.000677	0.0102	CbGeAlD
Dihydroergotamine—HTR1A—central nervous system—autistic disorder	0.000651	0.00978	CbGeAlD
Dihydroergotamine—HTR1B—brain—autistic disorder	0.000641	0.00962	CbGeAlD
Dihydroergotamine—HTR1A—cerebellum—autistic disorder	0.000637	0.00956	CbGeAlD
Dihydroergotamine—Ergotamine—HTR1B—autistic disorder	0.000634	0.0945	CrCbGaD
Dihydroergotamine—HTR1D—brain—autistic disorder	0.00062	0.00931	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR1B—autistic disorder	0.000611	0.0911	CrCbGaD
Dihydroergotamine—Bromocriptine—DRD3—autistic disorder	0.000593	0.0884	CrCbGaD
Dihydroergotamine—Bromocriptine—DRD1—autistic disorder	0.000583	0.0868	CrCbGaD
Dihydroergotamine—HTR2B—brain—autistic disorder	0.000577	0.00866	CbGeAlD
Dihydroergotamine—HTR1A—brain—autistic disorder	0.000517	0.00776	CbGeAlD
Dihydroergotamine—ADRA2A—head—autistic disorder	0.0005	0.00751	CbGeAlD
Dihydroergotamine—ABCB1—forebrain—autistic disorder	0.000487	0.00731	CbGeAlD
Dihydroergotamine—CYP3A4—digestive system—autistic disorder	0.000483	0.00725	CbGeAlD
Dihydroergotamine—ADRA2A—nervous system—autistic disorder	0.000474	0.00712	CbGeAlD
Dihydroergotamine—ADRA2A—central nervous system—autistic disorder	0.000457	0.00685	CbGeAlD
Dihydroergotamine—ABCB1—telencephalon—autistic disorder	0.000448	0.00672	CbGeAlD
Dihydroergotamine—ADRA2A—cerebellum—autistic disorder	0.000446	0.0067	CbGeAlD
Dihydroergotamine—CYP3A4—nervous system—autistic disorder	0.000373	0.0056	CbGeAlD
Dihydroergotamine—ADRA2A—brain—autistic disorder	0.000362	0.00544	CbGeAlD
Dihydroergotamine—CYP3A4—central nervous system—autistic disorder	0.000359	0.0054	CbGeAlD
Dihydroergotamine—ABCB1—digestive system—autistic disorder	0.000342	0.00513	CbGeAlD
Dihydroergotamine—Ergotamine—HTR2A—autistic disorder	0.000329	0.049	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR2A—autistic disorder	0.000317	0.0473	CrCbGaD
Dihydroergotamine—ABCB1—head—autistic disorder	0.000279	0.00418	CbGeAlD
Dihydroergotamine—ABCB1—nervous system—autistic disorder	0.000264	0.00397	CbGeAlD
Dihydroergotamine—ABCB1—central nervous system—autistic disorder	0.000254	0.00382	CbGeAlD
Dihydroergotamine—ABCB1—cerebellum—autistic disorder	0.000249	0.00373	CbGeAlD
Dihydroergotamine—ABCB1—brain—autistic disorder	0.000202	0.00303	CbGeAlD
Dihydroergotamine—HTR2B—Signaling Pathways—ADRB2—autistic disorder	1.41e-05	0.000109	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF2—autistic disorder	1.4e-05	0.000109	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CG—autistic disorder	1.39e-05	0.000109	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—OPRM1—autistic disorder	1.38e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL5—autistic disorder	1.38e-05	0.000107	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—UPB1—autistic disorder	1.36e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CALCA—autistic disorder	1.36e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PLA2G4A—autistic disorder	1.36e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—RORA—autistic disorder	1.36e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PLA2G4A—autistic disorder	1.35e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PLA2G4A—autistic disorder	1.34e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—POMC—autistic disorder	1.33e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—IL2—autistic disorder	1.32e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MEF2C—autistic disorder	1.32e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PRKCB—autistic disorder	1.32e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PLA2G4A—autistic disorder	1.32e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AVP—autistic disorder	1.32e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—IL2—autistic disorder	1.31e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF2—autistic disorder	1.31e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MEF2C—autistic disorder	1.31e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR2A—autistic disorder	1.31e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ITGB3—autistic disorder	1.29e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—IL2—autistic disorder	1.29e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MEF2C—autistic disorder	1.29e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ITGB3—autistic disorder	1.28e-05	9.96e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MAOB—autistic disorder	1.27e-05	9.89e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ASMT—autistic disorder	1.27e-05	9.86e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM5—autistic disorder	1.27e-05	9.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CG—autistic disorder	1.27e-05	9.85e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GZMB—autistic disorder	1.26e-05	9.85e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ITGB3—autistic disorder	1.25e-05	9.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PLA2G4A—autistic disorder	1.24e-05	9.67e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—OXT—autistic disorder	1.23e-05	9.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR1B—autistic disorder	1.23e-05	9.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IL2—autistic disorder	1.22e-05	9.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—IL2—autistic disorder	1.21e-05	9.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MEF2C—autistic disorder	1.21e-05	9.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—POMC—autistic disorder	1.2e-05	9.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR2A—autistic disorder	1.2e-05	9.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL2—autistic disorder	1.2e-05	9.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRL—autistic disorder	1.2e-05	9.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR2A—autistic disorder	1.19e-05	9.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL2—autistic disorder	1.19e-05	9.3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC25A12—autistic disorder	1.19e-05	9.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR2A—autistic disorder	1.19e-05	9.23e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TPH2—autistic disorder	1.18e-05	9.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ITGB3—autistic disorder	1.18e-05	9.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR2A—autistic disorder	1.17e-05	9.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL2—autistic disorder	1.17e-05	9.1e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—DPYD—autistic disorder	1.16e-05	9.05e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC19A1—autistic disorder	1.16e-05	9.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PRKCB—autistic disorder	1.14e-05	8.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TSC2—autistic disorder	1.14e-05	8.9e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TSC1—autistic disorder	1.14e-05	8.89e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD1—autistic disorder	1.14e-05	8.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADRB2—autistic disorder	1.14e-05	8.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TSC2—autistic disorder	1.13e-05	8.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—LEP—autistic disorder	1.12e-05	8.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—APOE—autistic disorder	1.12e-05	8.71e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP19A1—autistic disorder	1.11e-05	8.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TSC2—autistic disorder	1.11e-05	8.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—APOE—autistic disorder	1.11e-05	8.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NTRK2—autistic disorder	1.11e-05	8.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—LEP—autistic disorder	1.11e-05	8.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD3—autistic disorder	1.11e-05	8.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR2A—autistic disorder	1.1e-05	8.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL2—autistic disorder	1.1e-05	8.55e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CG—autistic disorder	1.1e-05	8.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—APOE—autistic disorder	1.09e-05	8.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—LEP—autistic disorder	1.09e-05	8.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL5—autistic disorder	1.08e-05	8.43e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CACNA1C—autistic disorder	1.08e-05	8.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AVP—autistic disorder	1.07e-05	8.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CALCA—autistic disorder	1.07e-05	8.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF2—autistic disorder	1.07e-05	8.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PRKCB—autistic disorder	1.06e-05	8.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PRKCB—autistic disorder	1.05e-05	8.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TSC2—autistic disorder	1.04e-05	8.13e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—POMC—autistic disorder	1.04e-05	8.12e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PRKCB—autistic disorder	1.04e-05	8.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—COMT—autistic disorder	1.03e-05	8.06e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADSL—autistic disorder	1.03e-05	8.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTP1—autistic disorder	1.03e-05	8.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MAOA—autistic disorder	1.03e-05	8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PRKCB—autistic disorder	1.03e-05	7.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—LEP—autistic disorder	1.02e-05	7.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—APOE—autistic disorder	1.02e-05	7.95e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—XDH—autistic disorder	1.01e-05	7.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—APC—autistic disorder	1.01e-05	7.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CG—autistic disorder	1.01e-05	7.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PLA2G4A—autistic disorder	1.01e-05	7.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—APC—autistic disorder	1e-05	7.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CG—autistic disorder	1e-05	7.8e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CAT—autistic disorder	1e-05	7.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGF—autistic disorder	9.98e-06	7.77e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CG—autistic disorder	9.94e-06	7.74e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—STX1A—autistic disorder	9.94e-06	7.74e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NPAS2—autistic disorder	9.94e-06	7.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGF—autistic disorder	9.9e-06	7.71e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—DHFR—autistic disorder	9.82e-06	7.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CG—autistic disorder	9.81e-06	7.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—APC—autistic disorder	9.81e-06	7.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—IL2—autistic disorder	9.8e-06	7.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MEF2C—autistic disorder	9.79e-06	7.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGF—autistic disorder	9.7e-06	7.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PRKCB—autistic disorder	9.63e-06	7.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—POMC—autistic disorder	9.61e-06	7.48e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TCN2—autistic disorder	9.6e-06	7.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ITGB3—autistic disorder	9.54e-06	7.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—POMC—autistic disorder	9.54e-06	7.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—POMC—autistic disorder	9.47e-06	7.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PLA2G4A—autistic disorder	9.46e-06	7.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTM1—autistic disorder	9.46e-06	7.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRL—autistic disorder	9.44e-06	7.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—POMC—autistic disorder	9.34e-06	7.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—MAPK1—autistic disorder	9.33e-06	7.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IGF1—autistic disorder	9.24e-06	7.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—APC—autistic disorder	9.22e-06	7.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CG—autistic disorder	9.22e-06	7.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—MAPK1—autistic disorder	9.2e-06	7.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IGF1—autistic disorder	9.17e-06	7.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADA—autistic disorder	9.16e-06	7.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—MAPK1—autistic disorder	9.13e-06	7.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGF—autistic disorder	9.11e-06	7.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GPX1—autistic disorder	9.06e-06	7.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF1—autistic disorder	8.98e-06	7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADRB2—autistic disorder	8.96e-06	6.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—MAPK1—autistic disorder	8.94e-06	6.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2A—autistic disorder	8.91e-06	6.94e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL2—autistic disorder	8.9e-06	6.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SERPINE1—autistic disorder	8.78e-06	6.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—POMC—autistic disorder	8.77e-06	6.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SERPINE1—autistic disorder	8.71e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SERPINE1—autistic disorder	8.53e-06	6.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TSC2—autistic disorder	8.46e-06	6.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF1—autistic disorder	8.44e-06	6.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AVP—autistic disorder	8.41e-06	6.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—MAPK1—autistic disorder	8.4e-06	6.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF2—autistic disorder	8.38e-06	6.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—autistic disorder	8.36e-06	6.51e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RORA—autistic disorder	8.35e-06	6.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—autistic disorder	8.28e-06	6.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—LEP—autistic disorder	8.28e-06	6.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—autistic disorder	8.01e-06	6.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PLA2G4A—autistic disorder	7.91e-06	6.16e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MAOB—autistic disorder	7.82e-06	6.09e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRKCB—autistic disorder	7.81e-06	6.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—autistic disorder	7.78e-06	6.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—IL2—autistic disorder	7.71e-06	6e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MEF2C—autistic disorder	7.7e-06	5.99e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP19A1—autistic disorder	7.69e-06	5.99e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ITGB3—autistic disorder	7.5e-06	5.84e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—HRAS—autistic disorder	7.49e-06	5.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APC—autistic disorder	7.47e-06	5.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CG—autistic disorder	7.47e-06	5.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGF—autistic disorder	7.39e-06	5.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HRAS—autistic disorder	7.39e-06	5.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HRAS—autistic disorder	7.33e-06	5.71e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TPH2—autistic disorder	7.27e-06	5.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HRAS—autistic disorder	7.18e-06	5.59e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DPYD—autistic disorder	7.16e-06	5.57e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—COMT—autistic disorder	7.15e-06	5.57e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTP1—autistic disorder	7.12e-06	5.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—POMC—autistic disorder	7.11e-06	5.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL2—autistic disorder	7.11e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MAOA—autistic disorder	7.1e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—autistic disorder	7.07e-06	5.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—autistic disorder	7.05e-06	5.49e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—autistic disorder	7.03e-06	5.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—autistic disorder	7.02e-06	5.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—autistic disorder	7e-06	5.45e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—autistic disorder	7e-06	5.45e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAT—autistic disorder	6.93e-06	5.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—autistic disorder	6.9e-06	5.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—autistic disorder	6.87e-06	5.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—autistic disorder	6.84e-06	5.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—MAPK1—autistic disorder	6.81e-06	5.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRAS—autistic disorder	6.74e-06	5.25e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—autistic disorder	6.69e-06	5.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTEN—autistic disorder	6.69e-06	5.21e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CACNA1C—autistic disorder	6.65e-06	5.18e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TSC2—autistic disorder	6.65e-06	5.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTEN—autistic disorder	6.63e-06	5.17e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PLA2G4A—autistic disorder	6.54e-06	5.09e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—autistic disorder	6.54e-06	5.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—autistic disorder	6.51e-06	5.07e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—autistic disorder	6.51e-06	5.07e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—autistic disorder	6.5e-06	5.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTEN—autistic disorder	6.5e-06	5.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—autistic disorder	6.49e-06	5.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—autistic disorder	6.45e-06	5.03e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX1—autistic disorder	6.26e-06	4.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKCB—autistic disorder	6.14e-06	4.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTEN—autistic disorder	6.1e-06	4.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DHFR—autistic disorder	6.05e-06	4.71e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APC—autistic disorder	5.87e-06	4.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—autistic disorder	5.87e-06	4.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGF—autistic disorder	5.81e-06	4.52e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—autistic disorder	5.78e-06	4.5e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—autistic disorder	5.59e-06	4.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRAS—autistic disorder	5.47e-06	4.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK1—autistic disorder	5.44e-06	4.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK1—autistic disorder	5.39e-06	4.2e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—autistic disorder	5.38e-06	4.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—autistic disorder	5.38e-06	4.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK1—autistic disorder	5.35e-06	4.17e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—autistic disorder	5.33e-06	4.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK1—autistic disorder	5.28e-06	4.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—autistic disorder	5.26e-06	4.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—autistic disorder	5.23e-06	4.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—autistic disorder	5.11e-06	3.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK1—autistic disorder	4.96e-06	3.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTEN—autistic disorder	4.95e-06	3.85e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—autistic disorder	4.86e-06	3.78e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP19A1—autistic disorder	4.74e-06	3.69e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTEN—autistic disorder	4.65e-06	3.62e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—autistic disorder	4.62e-06	3.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—COMT—autistic disorder	4.41e-06	3.43e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—autistic disorder	4.39e-06	3.42e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MAOA—autistic disorder	4.38e-06	3.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRAS—autistic disorder	4.36e-06	3.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRAS—autistic disorder	4.33e-06	3.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRAS—autistic disorder	4.3e-06	3.35e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAT—autistic disorder	4.27e-06	3.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRAS—autistic disorder	4.24e-06	3.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—autistic disorder	4.18e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—autistic disorder	4.14e-06	3.23e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—autistic disorder	4.13e-06	3.22e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—autistic disorder	4.11e-06	3.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—autistic disorder	4.06e-06	3.16e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLA2G4A—autistic disorder	4.03e-06	3.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—autistic disorder	4.03e-06	3.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK1—autistic disorder	4.02e-06	3.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRAS—autistic disorder	3.98e-06	3.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTEN—autistic disorder	3.89e-06	3.03e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX1—autistic disorder	3.86e-06	3.01e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—autistic disorder	3.81e-06	2.97e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—autistic disorder	3.69e-06	2.87e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—autistic disorder	3.56e-06	2.77e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—autistic disorder	3.32e-06	2.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRAS—autistic disorder	3.23e-06	2.52e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTEN—autistic disorder	3.22e-06	2.5e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK1—autistic disorder	3.16e-06	2.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—autistic disorder	3.09e-06	2.41e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—autistic disorder	2.99e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—autistic disorder	2.85e-06	2.22e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRAS—autistic disorder	2.54e-06	1.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—autistic disorder	2.43e-06	1.89e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—autistic disorder	2.27e-06	1.77e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTEN—autistic disorder	1.98e-06	1.54e-05	CbGpPWpGaD
